Efficacy of parenteral administration of bee venom in experimental arthritis in the rat: A comparison with methotrexate

Autor(es)

Yamasaki, Simone C. ^{[1, 2, 3]} ; Mendes, Mariana T. ^[1] ; Alponti, Rafaela F. ^[1] ; Silveira, Paulo F. ^[1]

Afiliação do(s) autor(es)

^[1] Inst Butantan, Unit Translat Endocrine Physiol & Pharmacol, Pharmacol Lab, BR-05503900 Sao Paulo, SP - Brazil

^[2] Inst Butantan, Interdept Biotechnol Program, BR-05508900 Sao Paulo - Brazil

^[3] Univ Sao Paulo, BR-05508900 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Toxicon; v. 98, p. 75-88, MAY 2015.
• Citações Web of Science: 1

Resumo

The use of bee venom (BV) to treat inflammation and pain in arthritis has become increasingly common. This study aimed to compare the effects of BV and methotrexate (MTX), the most used disease-modifying anti-rheumatic drug, in arthritic rats. Edema, erythema, cyanosis, hyperalgesia, reduction of the body mass gain, high circulating tumor necrosis factor alpha (TNF-alpha.) and anti-type II collagen antibodies (AACII), and altered activity of basic (APB) and neutral (APN) aminopeptidases and dipeptidyl peptidase IV (DPPIV) are present in arthritic rats. MTX and/or BV do not affect AACII in healthy or arthritic individuals, but restores TNF-alpha to normal levels in arthritic rats. BV restores body mass gain to normal levels and MTX ameliorates body mass gain. BV contains DPPIV. BV restores APN in synovial fluid (SF) and in soluble fraction (S) from synovial tissue (ST), and DPPIV in solubilized membrane-bound fraction (M) from peripheral blood mononuclear cells (PBMCs). MTX restores APN of SF, as well as ameliorates APB of S-PBMCs, APN of S-ST and DPPIV of M-PBMCs. The combination therapy does not overcome the effects of BV or MTX alone on the peptidase activities. Edema is ameliorated by MTX or BV alone. MTX, but not BV, is effective in reducing hyperalgesia. Data show that anti-arthritic effects of BV at nonacupoints are not negligible when compared with MTX. (C) 2015 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 07/08311-4 - Anticorpo anti-colágeno tipo II e interleucina 6 no plasma e peptidases do plasma, líquido e membrana sinoviais e de leucócitos circulantes de ratos tratados com colágeno tipo II e veneno de Apis mellifera
• Beneficiário: Paulo Flávio Silveira
• Modalidade de apoio: Auxílio à Pesquisa - Regular